Latest news articles

Added 5 days ago Drug news

Actelion Pharma withdraws filing of Opsumit for CTEPH

Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has announced its decision to voluntarily withdraw...

Added 1 month ago Drug news

FDA approves Xarelto to help prevent blood clots in acutely ill medical patients.- BayerHealthCare + Janssen R&D

Bayer AG and its development partner Janssen Research & Development, LLC announced that the FDA has approved rivaroxaban (Xarelto) for...

Added 5 months ago Drug news

Post-hoc analysis of GRIPHON study for Uptravi

Actelion Pharmaceuticals has presented results of a post-hoc exploratory analysis of the GRIPHON study in patients with pulmonary arterial hypertension...

Search all news articles for Pulmonary heart disease
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

ESICM LIVES Highlights

ESICM LIVES Highlights

ESICM LIVES Congress 2018: Bringing you the latest news and insights from the 31st ESICM LIVES Congress, 20–24 October 2018 Paris, France.

Hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

Load more

Guidelines

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots) and deep vein thrombosis (DVT) in people aged 16 and over in hospital.

Added 9 years ago

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart R

The scope of this focused update of the 2014 AF Guideline includes revisions to the section on anticoagulation (because of the approval of new medications and thromboembolism protection devices), revisions to the section...

Added 3 months ago

British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE)

The British Thoracic Society (BTS) Guideline for the initial OP management of PE provides guidance on how to risk-stratify patients with suspected and confirmed PE and subsequently manage them in an OP or ambulatory care setting.

Added 1 year ago

Search all guidelines for Pulmonary heart disease
 

Journal articles

ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison.

Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at preventing the atherothrombotic complications in patients with a variety of coronary artery disease (CAD) manifestations.

Added 2 months ago

Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.

Warfarin, a vitamin K antagonist, is the most widely used oral anticoagulant in the world. It is cheap and effective, but its use is limited in many patients by unpredictable levels of anticoagulation, which increases the risk of thromboembolic...

Added 3 months ago

Edoxaban: a focused review of its clinical pharmacology.

Long-term anticoagulation treatment with warfarin has been associated with a number of limitations in clinical practice and there is a need for more convenient long-term anticoagulation treatment. One of the non-vitamin K oral...

Added 3 months ago

Search all journal articles for Pulmonary heart disease
 

Clinical trials

A Study to Investigate Different Doses of BAY1213790 to Prevent Blood Clots in Patients Undergoing Elective Total Knee Replacement Surgery (FOXTROT)

This study is to compare the study drug BAY1213790 to existing therapies, ie Enoxaparin or Apixaban for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).

Added 2 years ago

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) (EinsteinChoice)

This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.
Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism)...

Added 6 years ago

Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (EPCAT II)

In this study the investigators want to look at whether using aspirin instead of rivaroxaban (after initial treatment with rivaroxaban) works as well at preventing blood clots while also reducing risk of bleeding...

Added 1 year ago

Search all clinical trials for Pulmonary heart disease
 
Adam Jeffery

What is Overdiagnosis?

Overdiagnosis is the diagnosis of disease that will cause neither morbidity nor mortality during a patient’s lifetime. Doctors are trained to listen, examine, test, diagnose and treat patients, but we are not warned of the possible dangers of “diseases”, the diagnosis of which will not benefit the patient and may also lead to harm. I would argue that the Hippocratic oath, in particular “Primum non nocere” (first, do no harm) should be at the forefront of every clinician’s mind when seeing patients.